Trials / Terminated
TerminatedNCT04906980
A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus (DENV) ribonucleic acid (RNA) in primary DENV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64281802 | JNJ-64281802 will be administered orally. |
| DRUG | Placebo | Matching placebo (PEG400) will be administered orally. |
Timeline
- Start date
- 2022-01-24
- Primary completion
- 2022-09-24
- Completion
- 2023-03-21
- First posted
- 2021-05-28
- Last updated
- 2024-03-01
- Results posted
- 2024-03-01
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04906980. Inclusion in this directory is not an endorsement.